Progesterone receptor variants associated with the PROGINS haplotype exhibit functional properties similar to those of wild-type progesterone receptor

Pharmacogenetics and Genomics

Volumn 22, Issue 8, 2012, Pages 629-641

  Stenzig, Justus ^a   Schweikert, Andreas ^b   Piasecki, Angelika ^a   Höppner, Grit ^a   Eschenhagen, Thomas ^a   Rau, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

breast cancer; endometriosis; ovarian cancer; progesterone receptor; PROGINS

Indexed keywords

HORMONE BINDING PROTEIN; LEUCINE; MESSENGER RNA; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROTEIN KINASE P60; SERINE; THREONINE; VALINE;

ADENOVIRUS; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRON; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION; WILD TYPE;

ADENOVIRIDAE;

EID: 84863825464     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283558256     Document Type: Article

References (84)

1. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6:229-239. (Pubitemid 39440251)
2. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006; 20:207-225. (Pubitemid 43380597)
3. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990; 11:266-301. (Pubitemid 20182871)
4. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997; 18:502-519. (Pubitemid 27349554)
5. Pepe GJ, Albrecht ED. Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocr Rev 1995; 16:608-648.
6. Tsutsui K. Progesterone biosynthesis and action in the developing neuron. Endocrinology 2008; 149:2757-2761. (Pubitemid 351724488)
7. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240:889-895.
8. Bouchard P. Progesterone and the progesterone receptor. J Reprod Med 1999; 44:153-157. (Pubitemid 29116021)
9. Carson-Jurica MA, Schrader WT, O'Malley BW. Steroid receptor family: structure and functions. Endocr Rev 1990; 11:201-220. (Pubitemid 20182869)
10. Gronemeyer H. Transcription activation by estrogen and progesterone receptors. Annu Rev Genet 1991; 25:89-123. (Pubitemid 21903716)
11. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63:451-486. (Pubitemid 24218640)
12. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990; 9:1603-1614.
13. Misrahi M, Atger M, d'Auriol L, Loosfelt H, Meriel C, Fridlansky F, et al. Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem Biophys Res Commun 1987; 143:740-748. (Pubitemid 17045810)
14. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 1994; 8:1347-1360. (Pubitemid 24335078)
15. Goldman S, Shalev E. Progesterone receptor profile in the decidua and fetal membrane. Front Biosci 2007; 12:634-648. (Pubitemid 46852811)
16. Samalecos A, Gellersen B. Systematic expression analysis and antibody screening do not support the existence of naturally occurring progesterone receptor (PR)-C, PR-M, or other truncated PR isoforms. Endocrinology 2008; 149:5872-5887.
17. Chappell PE, Lydon JP, Conneely OM, O'Malley BW, Levine JE. Endocrine defects in mice carrying a null mutation for the progesterone receptor gene. Endocrinology 1997; 138:4147-4152. (Pubitemid 27408454)
18. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr., et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995; 9:2266-2278.
19. Conneely OM, Mulac-Jericevic B, Lydon JP, De Mayo FJ. Reproductive functions of the progesterone receptor isoforms: lessons from knockout mice. Mol Cell Endocrinol 2001; 179:97-103. (Pubitemid 32564956)
20. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000; 289:1751-1754.
21. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002; 277:5209-5218. (Pubitemid 34968565)
22. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell-and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993; 7:1244-1255. (Pubitemid 23319107)
23. Romano A, Delvoux B, Fischer DC, Groothuis P. The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol 2007; 38:331-350. (Pubitemid 46351613)
24. Lee E, Hsu C, Haiman CA, Razavi P, Horn-Ross PL, Van Den Berg D, et al. Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach. Carcinogenesis 2010; 31:1392-1399.
25. Aruna M, Nagaraja T, Andal S, Tarakeswari S, Sirisha PV, Reddy AG, et al. Role of progesterone receptor polymorphisms in the recurrent spontaneous abortions: Indian case. PLoS One 2010; 5:e8712.
26. Su MT, Lee IW, Chen YC, Kuo PL. Association of progesterone receptor polymorphism with idiopathic recurrent pregnancy loss in Taiwanese Han population. J Assist Reprod Genet 2010; 28:239-243.
27. Near AM,Wu AH, Templeman C, Van Den Berg DJ, Doherty JA, Rossing MA, et al. Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertil Steril 2011; 95:40-45.
28. Rockwell LC, Rowe EJ, Arnson K, Jackson F, Froment A, Ndumbe P, et al. Worldwide distribution of allelic variation at the progesterone receptor locus and the incidence of female reproductive cancers. Am J Hum Biol 2012; 24:42-51.
29. Rowe SM, Coughlan SJ, McKenna NJ, Garrett E, Kieback DG, Carney DN, et al. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res 1995; 55:2743-2745.
30. McKenna NJ, Kieback DG, Carney DN, Fanning M, McLinden J, Headon DR. A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br J Cancer 1995; 71:451-455.
31. Fuqua SA, Hill SM, Chamness GC, Benedix MG, Greene GL, O'Malley BW, et al. Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors. J Natl Cancer Inst 1991; 83:1157-1160.
32. Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis 2001; 22:717-721. (Pubitemid 32447918)
33. De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA 2002; 99:12263-12268.
34. Modugno F. Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: a HuGE review. Am J Epidemiol 2004; 159:319-335. (Pubitemid 38200765)
35. Schweikert A, Rau T, Berkholz A, Allera A, Daufeldt S,Wildt L. Association of progesterone receptor polymorphism with recurrent abortions. Eur J Obstet Gynecol Reprod Biol 2004; 113:67-72. (Pubitemid 38281197)
36. Pearce CL, Wu AH, Gayther SA, Bale AE, Beck PA, Beesley J, et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer 2008; 98: 282-288. (Pubitemid 351161257)
37. Agoulnik IU, Tong XW, Fischer DC, Korner K, Atkinson NE, Edwards DP, et al. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 2004; 89:6340-6347. (Pubitemid 39628457)
38. Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, et al. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev 2006; 15:675-682.
39. Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB. Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res 2000; 60:2348-2350. (Pubitemid 30262419)
40. De Vivo I, Hankinson SE, Colditz GA, Hunter DJ. The progesterone receptor Val660-Leu polymorphism and breast cancer risk. Breast Cancer Res 2004; 6:R636-R639.
41. Spurdle AB, Hopper JL, Chen X, McCredie MR, Giles GG, Venter DJ, et al. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women. Cancer Epidemiol Biomarkers Prev 2002; 11:439-443. (Pubitemid 34517938)
42. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087-1093. (Pubitemid 47014426)
43. Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW. Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 2005; 161:442-451. (Pubitemid 40315615)
44. Manolitsas TP, Englefield P, Eccles DM, Campbell IG. No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br J Cancer 1997; 75:1398-1399. (Pubitemid 27179837)
45. Lancaster JM, Berchuck A, Carney ME,Wiseman R, Taylor JA. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. Br J Cancer 1998; 78:277. (Pubitemid 28302270)
46. Tong D, Fabjani G, Heinze G, Obermair A, Leodolter S, Zeillinger R. Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. Int J Cancer 2001; 95:394-397. (Pubitemid 33015112)
47. Pearce CL, Hirschhorn JN, Wu AH, Burtt NP, Stram DO, Young S, et al. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. J Natl Cancer Inst 2005; 97:51-59.
48. Johnatty SE, Spurdle AB, Beesley J, Chen X, Hopper JL, Duffy DL, et al. Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies. Breast Cancer Res Treat 2008; 109:91-99. (Pubitemid 351538757)
49. Wieser F, Schneeberger C, Tong D, Tempfer C, Huber JC, Wenzl R. PROGINS receptor gene polymorphism is associated with endometriosis. Fertil Steril 2002; 77:309-312. (Pubitemid 34083553)
50. Lattuada D, Somigliana E, Vigano P, Candiani M, Pardi G, Di Blasio AM. Genetics of endometriosis: a role for the progesterone receptor gene polymorphism PROGINS? Clin Endocrinol (Oxf) 2004; 61:190-194. (Pubitemid 39093113)
51. Van Kaam KJ, Romano A, Schouten JP, Dunselman GA, Groothuis PG. Progesterone receptor polymorphism +331G/A is associated with a decreased risk of deep infiltrating endometriosis. Hum Reprod 2007; 22:129-135. (Pubitemid 44942676)
52. Petz LN, Nardulli AM. Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol 2000; 14:972-985. (Pubitemid 32250515)
53. Norris J, Fan D, Aleman C, Marks JR, Futreal PA, Wiseman RW, et al. Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem 1995; 270:22777-22782.
54. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005; 122:33-43. (Pubitemid 40977938)
55. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, et al. New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 1994; 54:3868-3877. (Pubitemid 24241209)
56. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36:59-74.
57. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95:2509-2514. (Pubitemid 28145972)
58. Hofmann MA, Brian DA. Sequencing PCR DNA amplified directly from a bacterial colony. Biotechniques 1991; 11:30-31.
59. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB. Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 1998; 273:10696-10701. (Pubitemid 28227684)
60. Faivre EJ, Daniel AR, Hillard CJ, Lange CA. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol 2008; 22:823-837. (Pubitemid 351482820)
61. Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, et al. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004; 24:7260-7274. (Pubitemid 39014451)
62. Giulianelli S, Vaque JP, Soldati R, Wargon V, Vanzulli SI, Martins R, et al. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the Cyclin D1/MYC promoters. Cancer Res 2012; 72:2416-2427.
63. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998; 17:2008-2018. (Pubitemid 28154530)
64. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001; 8:269-280. (Pubitemid 32831545)
65. Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, et al. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak-and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 2005; 25:4826-4840. (Pubitemid 40781085)
66. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP. The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 2007; 21:359-375. (Pubitemid 46184890)
67. Hunter T. A tail of two src's: mutatis mutandis. Cell 1987; 49:1-4.
68. Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P. Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med 2006; 44:883-887.
69. Zhou HB, Lee JH, Mayne CG, Carlson KE, Katzenellenbogen JA. Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget. J Med Chem 2010; 53:3349-3360.
70. Du Y, Li Q, Xiong B, Hui X, Wang X, Feng Y, et al. Aromatic beta-aminoketone derivatives as novel selective non-steroidal progesterone receptor antagonists. Bioorg Med Chem 2010; 18:4255-4268.
71. Carbajo P, Christensen K, Edwards DP, Skafar DF. Binding of [3H]progesterone to the human progesterone receptor: differences between individual and mixed isoforms. Endocrinology 1996; 137:2339-2346. (Pubitemid 26155767)
72. Scarpin KM, Graham JD, Mote PA, Clarke CL. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal 2009; 7:e009.
73. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005; 23:4215-4224. (Pubitemid 46211327)
74. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ,Watts CK, Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993; 13:3577-3587. (Pubitemid 23157295)
75. Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007; 27:466-480. (Pubitemid 46080117)
76. Bagchi MK, Tsai SY, Tsai MJ, O'Malley BW. Ligand and DNA-dependent phosphorylation of human progesterone receptor in vitro. Proc Natl Acad Sci USA 1992; 89:2664-2668.
77. Houseley J, Tollervey D. The many pathways of RNA degradation. Cell 2009; 136:763-776.
78. Weigel NL. Steroid hormone receptors and their regulation by phosphorylation. Biochem J 1996; 319 (Pt 3):657-667. (Pubitemid 26386174)
79. Zhang Y, Beck CA, Poletti A, Clement JPT, Prendergast P, Yip TT, et al. Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol 1997; 11:823-832. (Pubitemid 27225309)
80. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 2000; 97:1032-1037. (Pubitemid 30080807)
81. Shen T, Horwitz KB, Lange CA. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent downregulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol 2001; 21:6122-6131. (Pubitemid 34263512)
82. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004; 25:45-71. (Pubitemid 38292038)
83. Georgiakaki M, Chabbert-Buffet N, Dasen B, Meduri G, Wenk S, Rajhi L, et al. Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription. Mol Endocrinol 2006; 20:2122-2140. (Pubitemid 44286709)
84. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997; 11:693-705. (Pubitemid 27225297)